CA2524034A1 - Utilisations de composes modulant les canaux ioniques - Google Patents

Utilisations de composes modulant les canaux ioniques Download PDF

Info

Publication number
CA2524034A1
CA2524034A1 CA002524034A CA2524034A CA2524034A1 CA 2524034 A1 CA2524034 A1 CA 2524034A1 CA 002524034 A CA002524034 A CA 002524034A CA 2524034 A CA2524034 A CA 2524034A CA 2524034 A1 CA2524034 A1 CA 2524034A1
Authority
CA
Canada
Prior art keywords
ion channel
channel modulating
hydrogen
subject
modulating compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002524034A
Other languages
English (en)
Inventor
Gregory N. Beatch
Alan Ezrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiome Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2524034A1 publication Critical patent/CA2524034A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002524034A 2003-05-02 2004-05-03 Utilisations de composes modulant les canaux ioniques Abandoned CA2524034A1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US46715903P 2003-05-02 2003-05-02
US60/467,159 2003-05-02
US49339203P 2003-08-07 2003-08-07
US60/493,392 2003-08-07
US51648603P 2003-10-31 2003-10-31
US51624803P 2003-10-31 2003-10-31
US60/516,248 2003-10-31
US60/516,486 2003-10-31
US52691103P 2003-12-03 2003-12-03
US60/526,911 2003-12-03
US52716903P 2003-12-04 2003-12-04
US60/527,169 2003-12-04
US52825103P 2003-12-08 2003-12-08
US60/528,251 2003-12-08
US54494104P 2004-02-13 2004-02-13
US60/544,941 2004-02-13
US55940504P 2004-04-01 2004-04-01
US60/559,405 2004-04-01
PCT/US2004/013731 WO2004098525A2 (fr) 2003-05-02 2004-05-03 Utilisations de composes modulant les canaux ioniques

Publications (1)

Publication Number Publication Date
CA2524034A1 true CA2524034A1 (fr) 2004-11-18

Family

ID=33437324

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002524034A Abandoned CA2524034A1 (fr) 2003-05-02 2004-05-03 Utilisations de composes modulant les canaux ioniques

Country Status (2)

Country Link
CA (1) CA2524034A1 (fr)
WO (1) WO2004098525A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK285908B6 (sk) 1998-04-01 2007-10-04 Nortran Pharmaceuticals Inc. Aminocyklohexyléterová zlúčenina, kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny pri výrobe liečiva a pri liečbe
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
KR101059379B1 (ko) 2003-05-02 2011-08-26 카디오메 파마 코포레이션 아미노사이클로헥실 에테르 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7674820B2 (en) 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005094897A2 (fr) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Derives de composes de modulation des canaux ioniques, compositions pharmaceutiques et utilisations
US8058304B2 (en) 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
EP1729815A2 (fr) 2004-04-01 2006-12-13 Cardiome Pharma Corp. Promedicaments de composes modulant les canaux ioniques et leurs utilisations
US7754897B2 (en) 2005-06-15 2010-07-13 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US8263638B2 (en) * 2004-11-08 2012-09-11 Cardiome Pharma Corp. Dosing regimens for ion channel modulating compounds
US8692002B2 (en) * 2004-11-18 2014-04-08 Cardiome Pharma Corp. Synthetic process for aminocyclohexyl ether compounds
KR20100017648A (ko) * 2007-05-04 2010-02-16 카디오메 파마 코포레이션 부정맥을 막기 위한 이온 채널 조절 화합물의 지속 방출성 구강 제형 및 관련 방법
WO2009018547A1 (fr) * 2007-08-01 2009-02-05 Cardiome Pharma Corp. Formulations à libération prolongée pour la prévention d'arythmies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268590A1 (fr) * 1999-04-12 2000-10-12 Nortran Pharmaceuticals Inc. Composes de regulation des canaux ioniques et utilisations de ces produits

Also Published As

Publication number Publication date
WO2004098525A2 (fr) 2004-11-18
WO2004098525A9 (fr) 2005-01-20
WO2004098525A3 (fr) 2005-04-14

Similar Documents

Publication Publication Date Title
US8188140B2 (en) Uses of ion channel modulating compounds
US7687536B2 (en) Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
CA2524034A1 (fr) Utilisations de composes modulant les canaux ioniques
EP1087934B1 (fr) Composes d'aminocyclohexyl ether et leurs applications
US20050154009A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
KR20160108611A (ko) 심방세동의 치료 방법
US7057053B2 (en) Ion channel modulating compounds and uses thereof
EP2501381B1 (fr) Traitement de la fibrillation atriale
JP5680412B2 (ja) レオヌリンの使用およびその組成物
RU2213560C2 (ru) Фармацевтическая композиция, содержащая сочетание правовращающего и левовращающего изомеров соталола
CA2370834C (fr) Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression
US20090041841A1 (en) Controlled release tablet formulations for the prevention of arrhythmias
CA2720410A1 (fr) Utilisation d'une combinaison d'udenafil et d'alfuzosine ou d'oxybutynine dans le traitement d'une vessie hyperactive
KR100352898B1 (ko) 새로운3-벤조일-3,7-디아자바이사이클로[3,3,1]노난-화합물을함유하는약제
EP1868598B1 (fr) Schemas posologiques pour modulateurs de canaux ioniques pour le traitement de la fibrillation auriculaire aigue chez l'homme
RU2358732C2 (ru) Жидкие фармацевтические композиции, содержащие производные 3,7-диазабицикло(3,3,1)нонана, для лечения антиаритмических реакций
CA2533492A1 (fr) Utilisation de composes de 3,7-diazabicyclo[3,3,1]nonane pour traiter et/ou prevenir des evenements arythmiques chez des patients humains males
MXPA05011808A (en) Uses of ion channel modulating compounds
EA028995B1 (ru) Соль тезофензина и оптически активных ацетиламинокислот, их применение для лечения и/или профилактики нарушений, связанных с ожирением
US20050054667A1 (en) Method of treating or inhibiting anti-arrhythmic events in male human patients
JP2002255819A (ja) 神経栄養因子的作用剤
ZA200300220B (en) Compounds for the treatment of addictive disorders.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20190503